ReviewWorld journal of gastroenterology2023
Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The association between oral hygiene and metabolic dysfunction-associated steatotic liver disease - a systematic review.BMC oral health · 2026Pooled it
- Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Oral virome in health and disease.Journal of the American Dental Association (1939) · 2026Review
- Beyond the Lungs: ICU Oral Care and Gut Resilience-A Hypothesis-Generating Narrative Review.Microorganisms · 2026Review
- Metagenomics in the Interplay Among Oral and Gut Dysbiosis.Metabolites · 2026Review
- The Effects of Periodontal Treatment on Psoriasis: A Systematic Review of Limited Clinical and Preclinical Evidence.Journal of clinical medicine · 2026Review
- Hyperglycemic microenvironment-driven periodontal tissue defects: pathogenic mechanisms and therapeutic advances.Frontiers in dental medicine · 2026Review
- The oral-gut-liver axis: linking periodontal microbiota to the pathogenesis of liver diseases.Frontiers in medicine · 2026Review
- Periodontal status and microbial profiles across the clinical spectrum of liver cirrhosis.Journal of oral microbiology · 2026Article
- The Oral Microbiome, Oral Hyperpermeability, and Periodontitis in Metabolic Syndrome.Advances in experimental medicine and biology · 2026Review
- The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma.Gut microbes · 2025Review
- Liver Disease and Periodontal Pathogens: A Bidirectional Relationship Between Liver and Oral Microbiota.Dentistry journal · 2025Review
- ORMCKB: A Knowledge Database for Personalized Medicine in Deciphering the Oral Microbiome-Disease Axis.Interdisciplinary sciences, computational life sciences · 2025Article
- Recent advances in therapeutic probiotics: insights from human trials.Clinical microbiology reviews · 2025Review
- Interaction Between Periodontitis and MASLD: Pathophysiological Associations and Possibilities of Prevention and Therapy.Biomedicines · 2025Review
- Microbiome composition and metabolic pathways in shallow and deep periodontal pockets.Scientific reports · 2025Article
- Nonalcoholic Fatty Liver Disease Increases the Risk of Lung Abscess: Findings from a Nationwide Cohort Study.Journal of clinical medicine · 2025Article
- Advances in orthodontic treatment for periodontal disease: a bibliometric analysis, emerging insights and clinical implications.Frontiers in dental medicine · 2025Article
- Role of gut microbiota dysbiosis in the pathogenesis of non-alcoholic fatty liver disease among obese individuals.Bioinformation · 2025Article
- Integrated oral-gut microbiota therapy: a novel perspective on preventing bacterial translocation for systemic disease management.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
A growing body of evidence from multiple areas proposes that periodontal disease, accompanied by oral inflammation and pathological changes in the microbiome, induces gut dysbiosis and is involved in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). A subgroup of NAFLD patients have a severely progressive form, namely nonalcoholic steatohepatitis (NASH), which is characterized by histological findings that include inflammatory cell infiltration and fibrosis. NASH has a high risk of further progression to cirrhosis and hepatocellular carcinoma. The oral microbiota may serve as an endogenous reservoir for gut microbiota, and transport of oral bacteria through the gastro-intestinal tract can set up a gut microbiome dysbiosis. Gut dysbiosis increases the production of potential hepatotoxins, including lipopolysaccharide, ethanol, and other volatile organic compounds such as acetone, phenol and cyclopentane. Moreover, gut dysbiosis increases intestinal permeability by disrupting tight junctions in the intestinal wall, leading to enhanced translocation of these hepatotoxins and enteric bacteria into the liver through the portal circulation. In particular, many animal studies support that oral administration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.